Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SHBG | P04278 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28897816 | 0.81 | TP53 (0.47) | ALDH1A1EPHX2TSHRNPSR1EPHX1 | |
| SCHEMBL28842009 | 0.79 | TSHR (0.39) | ALDH1A1EPHX2TSHRNPSR1EPHX1 | |
| SCHEMBL26870367 | 0.79 | SHBG (0.39) | ALDH1A1EPHX2EPHX1SHBGKDM4E | |
| SCHEMBL31547019 | 0.79 | SHBG (0.39) | ALDH1A1EPHX2EPHX1SHBGKDM4E | |
| SCHEMBL1986462 | 0.77 | EPHX1 (0.40) | ALDH1A1EPHX2TSHRNPSR1EPHX1 | |
| SCHEMBL11843181 | 0.77 | EPHX1 (0.38) | ALDH1A1EPHX2NPSR1EPHX1TP53 | |
| SCHEMBL11843198 | 0.77 | EPHX1 (0.35) | ALDH1A1EPHX2TSHRNPSR1EPHX1 | |
| SCHEMBL2648204 | 0.76 | ALDH1A1 (0.46) | ALDH1A1TSHRNPSR1L3MBTL1THRB | |
| SCHEMBL31547036 | 0.76 | ALDH1A1 (0.46) | ALDH1A1TSHRNPSR1L3MBTL1THRB | |
| SCHEMBL10557463 | 0.75 | EPHX1 (0.41) | ALDH1A1EPHX2TSHRNPSR1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4291157-B1 | FRAGRANCE DELIVERY COMPOSITIONS | TAMINCO BV (BE) | 2025-03-19 | — | — | EP | disclosed |
| US-20240148630-A1 | FRAGRANCE DELIVERY COMPOSITIONS | TAMINCO BV (BE) | 2024-05-09 | — | — | US | disclosed |
| EP-4291157-A1 | FRAGRANCE DELIVERY COMPOSITIONS | Taminco BV (BE) | 2023-12-20 | — | — | EP | disclosed |
| WO-2022171707-A1 | FRAGRANCE DELIVERY COMPOSITIONS | TAMINCO BV (BE) | 2022-08-18 | — | — | WO | disclosed |
| CN-113575344-A | Anti-season seedling transplanting method by using growth regulator to pick leaves | 北京市园林绿化集团有限公司 | 2021-11-02 | — | — | CN | disclosed |
| US-20120083529-A1 | USE OF JASMONATE ESTER DERIVATIVES FOR TREATING BENIGN HYPERPROLIFERATIVE SKIN DISORDERS | SEPAL PHARMA LTD (IL) | 2012-04-05 | — | — | US | disclosed |
| WO-2010143180-A1 | USE OF JASMONATE ESTER DERIVATIVES FOR TREATING BENIGN HYPERPROLIFERATIVE SKIN DISORDERS | SEPAL PHARMA LTD. (IL) | 2010-12-16 | — | — | WO | disclosed |
| EP-2037903-A1 | COMBINATION METHODS OF TREATING CANCER | Ramot at Tel-Aviv University Ltd. (IL) | 2009-03-25 | — | — | EP | disclosed |
| WO-2009019693-A2 | ANALGESIC EFFECT OF JASMONATE DERIVATIVES | SEPAL PHARMA SA (FR) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008007367-A1 | COMBINATION METHODS OF TREATING CANCER | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083529-A1 | USE OF JASMONATE ESTER DERIVATIVES FOR TREATING BENIGN HYPERPROLIFERATIVE SKIN DISORDERS | MYC, KRT18, DGKK | ALDH1A1 2744/4885EPHX2 1095/4885TSHR 4800/4885 |
| US-20240148630-A1 | FRAGRANCE DELIVERY COMPOSITIONS | F12, P4HA1, INO80C | ALDH1A1 722/4885EPHX2 3569/4885TSHR 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.